Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
Romiplostim is a second-generation thrombopoietic receptor agonist that exerts its therapeutic effect by stimulating megakaryopoiesis. We report a patient with immune thrombocytopenic purpura refractory to other therapies including splenectomy, which was successfully managed with romiplostim. More specifically, the patient's platelet count showed a 3-fold increase within 7 days following the first dose of romiplostim (from 33 x 10(9)/l to 96 x 10(9)/l). Romiplostin is a new trombopoietin peptide mimetic drug, which seems to be very effective for the management of refractory chronic ITP in adults.